A small molecule promotes cartilage extracellular matrix generation and inhibits osteoarthritis development

TLDR

Osteoarthritis is driven by extracellular matrix degradation, and no disease‑modifying therapy currently exists. The study introduces BNTA, a small molecule that modulates extracellular matrix production. BNTA stimulates production of ECM components in osteoarthritic chondrocytes and explants while suppressing inflammatory mediators. Intra‑articular BNTA delayed osteoarthritis progression in a rat model, with SOD3 mediating its effect on ECM synthesis, highlighting BNTA and SOD3 as promising therapeutic targets.

Abstract

Abstract Degradation of extracellular matrix (ECM) underlies loss of cartilage tissue in osteoarthritis, a common disease for which no effective disease-modifying therapy currently exists. Here we describe BNTA, a small molecule with ECM modulatory properties. BNTA promotes generation of ECM components in cultured chondrocytes isolated from individuals with osteoarthritis. In human osteoarthritic cartilage explants, BNTA treatment stimulates expression of ECM components while suppressing inflammatory mediators. Intra-articular injection of BNTA delays the disease progression in a trauma-induced rat model of osteoarthritis. Furthermore, we identify superoxide dismutase 3 (SOD3) as a mediator of BNTA activity. BNTA induces SOD3 expression and superoxide anion elimination in osteoarthritic chondrocyte culture, and ectopic SOD3 expression recapitulates the effect of BNTA on ECM biosynthesis. These observations identify SOD3 as a relevant drug target, and BNTA as a potential therapeutic agent in osteoarthritis.